Abstract:Previous investigations have demonstrated that endogenous inhibitors of nitric oxide synthase (NOS), such as asymmetric dimethylarginine (ADMA), contribute importantly to endothelial dysfunction, and that fenofibrate has a protective effect on the endothelium in rats treated with low-density lipoprotein (LDL) by reducing ADMA levels. In the present study, we explored further the possible mechanism underlying inhibition of ADMA generation by fenofibrate in cultured human umbilical vein endothelial cells (HUVECs). Endothelial injury was induced in cultured HUVECs by incubation with oxidative LDL (ox-LDL) and the levels of ADMA, lactate dehydrogenase (LDH), NO and tumour necrosis factor-alpha (TNF-alpha) in the conditioned medium were measured. Cell viability and the activity of dimethylarginine dimethylaminohydrolase (DDAH) and nuclear factor-kappa B (NF-kappa B) in the cultured HUVECs were also determined. Incubation of HUVECs with ox-LDL (100 mu g/ml) for 24 h markedly elevated ADMA, LDH and TNF-alpha in the conditioned medium and significantly 886, a specific peroxisome proliferator-activated receptor-a (PPAR alpha) antagonist. The present results suggest that feno-fibrate inhibits ox-LDL-induced endothelial cell damage by decreasing ADMA and increasing DDAH activity, and the protective effects of fenofibrate on endothelial cells may be related to reduction of NF-kappa B activity by activation of the PPARa receptor.increased the activity of NF-kappa B, concomitantly with a significant decrease in the activity of DDAH and the content of NO. Pretreatment with fenofibrate ( 3, 10 or 30 mu M) significantly inhibited the increases in ADMA, LDH and TNF-alpha, attenuated the decreased levels of NO and the decreased activity of DDAH and prevented the activation of NF-kappa B. Similar effects were observed in the presence of pyrrolidine dithiocarbamate (PDTC, 10 mu M), an antagonist of NF-kappa B. The beneficial effects of fenofibrate on cultured endothelial cells were abolished by MK-886, a specific peroxisome proliferator-activated receptor-a (PPAR alpha) antagonist. The present results suggest that feno-fibrate inhibits ox-LDL-induced endothelial cell damage by decreasing ADMA and increasing DDAH activity, and the protective effects of fenofibrate on endothelial cells may be related to reduction of NF-kappa B activity by activation of the PPARa receptor.

The Protective Effect of Fenofibrate Against TNF-α-Induced CD40 Expression through SIRT1-Mediated Deacetylation of NF-κB in Endothelial Cells

PPARα Agonist Fenofibrate Attenuates TNF-α-induced CD40 Expression in 3T3-L1 Adipocytes Via the SIRT1-dependent Signaling Pathway

SIRT1 regulates CD40 expression induced by TNF-α via NF-ĸB pathway in endothelial cells.

Fenofibrate Inhibits Tumor Necrosis Factor-Alpha-induced Expression of CD40 and Matrix Metalloproteinase in Human Vascular Endothelial Cells.

Fenofibrate Improves Vascular Endothelial Function and Contractility in Diabetic Mice

Modulation of LPS-mediated Inflammation by Fenofibrate Via the TRIF-dependent TLR4 Signaling Pathway in Vascular Smooth Muscle Cells.

Activation of PPAR Alpha by Fenofibrate Inhibits Apoptosis in Vascular Adventitial Fibroblasts Partly Through SIRT1-mediated Deacetylation of FoxO1.

Sirt1 Regulates Tnf-Alpha-Induced Expression Of Cd40 In 3t3-L1 Adipocytes Via Nf-Kappa B Pathway

Ppar Alpha Activator Fenofibrate Modulates Angiotensin Ii-Induced Inflammatory Responses in Vascular Smooth Muscle Cells Via the Tlr4-Dependent Signaling Pathway

Fenoﬁbrate suppresses cellular metabolic memory of high glucose in diabetic retinopathy via a sirtuin 1-dependent signalling pathway

SIRT1 regulates TNF-α-induced expression of CD40 in 3T3-L1 adipocytes via NF-κB pathway.

Fenofibrate Decreases Asymmetric Dimethylarginine Level in Cultured Endothelial Cells by Inhibiting NF-κB Activity

Effect of Fenofibrate on LDL-induced Endothelial Dysfunction in Rats

Fenofibrate Ameliorated Systemic and Retinal Inflammation and Modulated Gut Microbiota in High-Fat Diet-Induced Mice

C-reactive Protein-Induced Expression of CD40-CD40L and the Effect of Lovastatin and Fenofibrate on It in Human Vascular Endothelial Cells.

Improvement of inflammatory responses associated with NF-κB pathway in kidneys from diabetic rats

Effect of Fenofibrate on Adiponectin Gene Expression and Endothelial Function in Diabetic Rats

Fenofibrate Partly Prevents Oxidized-Low Density Lipoprotein Induced Immune Maturation of Human Monocyte-Derived Dendritic Cell

PPARα Agonist Stimulated Angiogenesis by Improving Endothelial Precursor Cell Function Via a NLRP3 Inflammasome Pathway

Fenofibrate Attenuates Hepatic Fibrosis by PPAR-Α and TGF-β1/Smad Signaling Pathway Via Modulating Autophagy and Oxidative Stress

Fenofibrate ameliorates diabetic retinopathy by modulating Nrf2 signaling and NLRP3 inflammasome activation